Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 10, 2016 - Issue
Submit an article Journal homepage
99
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study

Hongrong Xu1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China
,
Lei Sheng1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China
,
Weili Chen1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China
,
Fei Yuan1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China
,
Mengjie Yang1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China
,
Hui Li1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China
,
Xuening Li1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
,
John Choi2 Department of Clinical Research & Development, Hua Medicine, Shanghai, People’s Republic of China
,
Guiyu Zhao2 Department of Clinical Research & Development, Hua Medicine, Shanghai, People’s Republic of China
,
Tianxin Hu2 Department of Clinical Research & Development, Hua Medicine, Shanghai, People’s Republic of China
,
Yongguo Li2 Department of Clinical Research & Development, Hua Medicine, Shanghai, People’s Republic of China
,
Yi Zhang2 Department of Clinical Research & Development, Hua Medicine, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
&
Li Chen2 Department of Clinical Research & Development, Hua Medicine, Shanghai, People’s Republic of China
 show all
Pages 1619-1626 | Published online: 09 May 2016

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Yixin Ren, Li Li, Li Wan, Yan Huang & Shuang Cao. (2022) Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists. Journal of Enzyme Inhibition and Medicinal Chemistry 37:1, pages 606-615.
Read now
Aoife Egan & Adrian Vella. (2019) TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes. Expert Opinion on Investigational Drugs 28:9, pages 741-747.
Read now

Articles from other publishers (3)

Yuming Wang, Xiaofei Su, Wenli Zhang, Yunting Zhou, Xiao Zhou, Wei Yang, Huiqin Li & Jianhua Ma. (2023) Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus. International Journal of Endocrinology 2023, pages 1-9.
Crossref
Yunfeng Yu, Xingyu Yang, Keke Tong, Shuang Yin, Gang Hu, Fei Zhang, Pengfei Jiang, Manli Zhou & Weixiong Jian. (2022) Efficacy and safety of dorzagliatin for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis. Frontiers in Cardiovascular Medicine 9.
Crossref
Ling Song, Yi Zhang, Ji Jiang, Shuang Ren, Li Chen, Dongyang Liu, Xijing Chen & Pei Hu. (2018) Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics. Clinical Pharmacokinetics 57:10, pages 1307-1323.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.